HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $660
3/31/2026
Impact: 70
Healthcare
HC Wainwright & Co. analyst Andrew S. Fein has maintained a 'Buy' rating on United Therapeutics (NASDAQ: UTHR) and increased the price target from $600 to $660.
AI summary, not financial advice
Share: